Vaxcyte
PCVX
Market cap $10.8B

86.83 USD

-5.85

6.31%

At close Nov 15, 4:00 PM EST

After hours

86.30

-0.53

0.61%

1 day

-6.31%

5 days

-18.60%

1 month

-24.82%

3 months

10.70%

6 months

21.22%

Year to date

37.96%

1 year

70.93%

5 years

232.05%

10 years

232.05%

About: Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Employees: 254

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,704 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

242% more first-time investments, than exits

New positions opened: 82 | Existing positions closed: 24

66% more capital invested

Capital invested by funds: $9.31B [Q2] → $15.5B (+$6.15B) [Q3]

53% more funds holding in top 10

Funds holding in top 10: 15 [Q2] → 23 (+8) [Q3]

48% more call options, than puts

Call options by funds: $90.6M | Put options by funds: $61.4M

47% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 86

22% more funds holding

Funds holding: 262 [Q2] → 320 (+58) [Q3]

2.09% less ownership

Funds ownership: 113.23% [Q2] → 111.14% (-2.09%) [Q3]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$129

49%

upside

Avg. target

$146

69%

upside

High target

$163

88%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Needham Joseph Stringer 42% 1-year accuracy 55 / 130 met price target	61%upside $140	Buy Reiterated	6 Nov 2024
Mizuho Salim Syed 41% 1-year accuracy 7 / 17 met price target	88%upside $163	Outperform Maintained	10 Sept 2024
B of A Securities Jason Gerberry 44% 1-year accuracy 11 / 25 met price target	61%upside $140	Buy Maintained	4 Sept 2024
Leerink Partners David Risinger 38% 1-year accuracy 3 / 8 met price target	76%upside $153	Outperform Maintained	3 Sept 2024
Jefferies Roger Song 43% 1-year accuracy 6 / 14 met price target	49%upside $129	Buy Maintained	3 Sept 2024

See Analyst Rankings

Financial journalist opinion

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 --

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 --

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Zacks Investment Research

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

See News Rankings

Charts implemented using Lightweight Charts™